Pagidipati, Neha J.
Taub, Pam R.
Ostfeld, Robert J.
Kirkpatrick, Carol F.
Article History
Accepted: 21 June 2024
First Online: 17 July 2024
Competing interests
: N.J.P. declares research support from Alnylam, Amgen, Bayer, Boehringer Ingelheim, Eggland’s Best, Eli Lilly, Novartis, Novo Nordisk and Merck; consultation/advisory panels for AstraZeneca, Bayer, Boehringer Ingelheim, CRISPR Therapeutics, Eli Lilly, Esperion, Merck, Novartis and Novo Nordisk; executive committee member for trials sponsored by Amgen and Novo Nordisk; data safety and monitoring board for trials sponsored by Johnson & Johnson and Novartis; and medical advisory board for Miga Health. P.R.T. is a consultant to Amgen, Bayer, Boehringer Ingelheim, Edwards, Esperion, Lilly, Medtronic, Merck, Novartis, Novo Nordisk and Sanofi; and is a founder and shareholder of Epirium Bio. R.J.O. declares research grants from Greenbaum Foundation and Purjes Foundation; research agreement with Beyond Meat; scientific advisory board of Mesuron, with stock option. C.F.K. declares no competing interests.